• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Biohaven Reports Positive Results from BHV-0223 Trial americanpharmaceuticalreview
    August 17, 2018
    Biohaven announced positive results from a double-blind, placebo-controlled, proof of concept clinical trial evaluating the effect of BHV-0223 in patients diagnosed with social anxiety disorder and public speaking anxiety while performing an anxiety-provo
  • Biohaven Doses First Subject in Bioequivalence Study with BHV-0223 americanpharmaceuticacreview
    November 07, 2017
    Biohaven is developing BHV-0223, a sublingual formulation of riluzole, as a potential treatment for patients with Amyotrophic Lateral Sclerosis (ALS).

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service